<SEC-DOCUMENT>0001615774-19-005851.txt : 20190417
<SEC-HEADER>0001615774-19-005851.hdr.sgml : 20190417
<ACCEPTANCE-DATETIME>20190417081922
ACCESSION NUMBER:		0001615774-19-005851
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20190416
FILED AS OF DATE:		20190417
DATE AS OF CHANGE:		20190417

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immuron Ltd
		CENTRAL INDEX KEY:			0001660046
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38104
		FILM NUMBER:		19752232

	BUSINESS ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
		BUSINESS PHONE:		61 03 9824 5254

	MAIL ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>s117460_6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Form
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO RULE 13a-16 OR 15d-16 UNDER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>THE
SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the Month of April 2019</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commission
File Number: 001-38104</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>IMMURON
LIMITED</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name
of Registrant)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Level
3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive office)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746; &nbsp;Form 40-F &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
&ldquo;Yes&rdquo; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMMURON
LIMITED</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>EXPLANATORY
NOTE</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immuron
Limited (the &ldquo;Company&rdquo;) published one announcement (the &ldquo;Public Notices&rdquo;) to the Australian Securities
Exchange on April 17, 2019 titled:&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Immuron
                                         Appoints CEO Dr. Gary S. Jacob to Board of Directors&rdquo;</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the Public Notice is attached as an exhibit to this report on Form 6-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
report on Form 6-K (including the exhibit hereto) shall not be deemed to be &ldquo;filed&rdquo; for purposes of the Securities
Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;) and shall not be incorporated by reference into any filing under
the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBITS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 8%; border-bottom: black 1pt solid; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit</B><BR>
    <B>Number</B></FONT></TD>
    <TD STYLE="width: 1%; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 91%; border-bottom: black 1pt solid; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><BR>
    <B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="s117460_ex99-1.htm">99.1</A></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="s117460_ex99-1.htm">Immuron Appoints CEO Dr. Gary S. Jacob to Board of Directors</A></FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURE</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMMURON LIMITED</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:&nbsp;&nbsp;April 17,
    2019</FONT></TD>
    <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:&nbsp;</FONT></TD>
    <TD STYLE="width: 46%; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Phillip Hains</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phillip Hains</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company Secretary</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>

    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>s117460_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="color: Red; font: 9pt Sans-Serif; margin: 0pt 0; text-align: center"><IMG SRC="img001_v1.jpg" ALT=""></P>

<P STYLE="color: Red; font: 9pt Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 20pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Immuron
Appoints CEO Dr. Gary S. Jacob to Board of Directors</B></FONT></P>

<P STYLE="font: 20pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: windowtext">Melbourne,
Australia, April 17, 2019: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing
and commercializing oral immunoglobulin therapeutics for the treatment of gut mediated diseases, </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">today
announced the appointment of Dr. Gary S. Jacob, CEO of Immuron Ltd. to the Board of Directors as a Director.</FONT></P>

<P STYLE="font: 12pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Jacob was appointed Chief Executive Officer of Immuron Ltd. on 19 November 2018 and this appointment to the Board is as envisaged
in his employment agreement.</FONT></P>

<P STYLE="font: 12pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
<FONT STYLE="color: black">material terms of Dr. Jacob&rsquo;s employment agreement are set out below as required by Listing Rule
3.16.4.</FONT></FONT></P>

<P STYLE="font: 12pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 9pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #231F20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ABOUT
IMMURON:</B>&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immuron
Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally
delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. Immuron has a novel
and safe technology platform with one commercial asset generating revenue. In Australia, Travelan&reg; is a listed medicine on
the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk of Travellers&rsquo; Diarrhea,
reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan&reg; is a licenced natural health
product (NPN 80046016) and is indicated to reduce the risk of Travellers&rsquo; Diarrhea. In the U.S., Travelan&reg; is sold as
a dietary supplement for digestive tract protection. Immuron&rsquo;s lead clinical candidate, IMM-124E, is presently in Phase
II trials in Severe Alcoholic Hepatitis (SAH) and Pediatric Nonalcoholic Fatty Liver Disease (NAFLD). The company now has plans
to develop a U.S. registration dossier for IMM-124E for Travellers&rsquo; Diarrhea. Immuron&rsquo;s second clinical-stage asset,
IMM-529, targets <I>Clostridium difficile </I>Infections (CDI), and is presently in a clinical trial in CDI patients. These products
together with the Company&rsquo;s other preclinical immunotherapy pipeline products currently under development targeting immune-related
and infectious diseases are anticipated to meet pressing needs in the global immunotherapy market.</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
- - END - - -</FONT></P>

<P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%"><P STYLE="color: #0079C1; font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPANY
                           CONTACT:</B></FONT></P>
        <P STYLE="color: #0079C1; font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="color: #231F20; font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Gary
        S. Jacob, Ph.D.</B>&nbsp;</FONT></P>
        <P STYLE="color: #231F20; font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
        Executive Officer&nbsp;</FONT></P>
        <P STYLE="color: #231F20; font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ph:
        +61 (0)3 9824 5254&nbsp;</FONT></P>
        <P STYLE="color: #231F20; font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">info@immuron.com
        &nbsp;</FONT></P></TD>
    <TD STYLE="width: 37%"><P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; color: #0079C1"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AUS
                           INVESTOR RELATIONS:</B></FONT></P>
        <P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; color: #0079C1"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; color: #231F20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Peter
        Taylor</B>&nbsp;</FONT></P>
        <P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; color: #231F20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NWR
        Communications&nbsp;</FONT></P>
        <P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; color: #231F20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ph:
        +61 (0)4 1203 6231&nbsp;</FONT></P>
        <P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">peter@nwrcommunications.com.au&nbsp;</FONT></P></TD>
    <TD STYLE="width: 31%"><P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #0079C1"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>USA
                           INVESTOR RELATIONS:</B></FONT></P>
        <P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #0079C1"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dave
        Gentry - CEO </B>&nbsp;</FONT></P>
        <P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RedChip
        Companies, Inc.&nbsp;</FONT></P>
        <P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
        Ph: +1 (407) 491 4498&nbsp;</FONT></P>
        <P STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">dave@redchip.com&nbsp;</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information visit: http://www.immuron.com.</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 31%; border-top: Black 1pt solid"><P STYLE="font: 8pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: gray"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 8pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: gray"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level
        3, 62 Lygon Street,&nbsp;</FONT></P>
        <P STYLE="font: 8pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: gray"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Carlton
        South, Victoria&nbsp;</FONT></P>
        <P STYLE="font: 8pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: gray"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AUSTRALIA
        &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3053&nbsp;</FONT></P></TD>
    <TD STYLE="width: 33%; border-top: Black 1pt solid"><P STYLE="color: gray; font: 8pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
                                                        <P STYLE="color: gray; font: 8pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>www.immuron.com</U>&nbsp;</FONT></P>
                                                        <P STYLE="color: gray; font: 8pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
        <P STYLE="color: gray; font: 8pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABN:
        80 063 114 045&nbsp;</FONT></P></TD>
    <TD STYLE="width: 36%; border-top: Black 1pt solid"><P STYLE="color: gray; font: 8pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="color: gray; font: 8pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Phone:
        + 61 (0)3 9824 5254</FONT></P>
        <P STYLE="font: 8pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right; color: gray"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Facsimile:
        + 61 (0)3 9822 7735</FONT></P></TD></TR>
</TABLE>


<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: right"><IMG SRC="img002_v1.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #231F20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORWARD-LOOKING
STATEMENTS:</B></FONT></P>

<P STYLE="font: 10pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify; color: #231F20"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 8pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release may contain &ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the Securities Act of
1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to,
any statements relating to our growth strategy and product development programs and any other statements that are not historical
facts. Forward-looking statements are based on management&rsquo;s current expectations and are subject to risks and uncertainties
that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual
results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain,
perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and
development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical
and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the
early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual
property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking
to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations
or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.</FONT></P>

<P STYLE="font: 8pt Calibri, Helvetica, Sans-Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 9.35pt 0pt 24.6pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Attachment
1</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 9.35pt 0pt 24.6pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 9.35pt 0pt 24.6pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Dr
Gary S. Jacob &ndash; Material terms of the employment agreement</B></FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 9.35pt 0pt 24.6pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; font: 12pt Times New Roman, Times, Serif; text-align: justify; border: Black 1pt solid; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Appointment
    Date</B></FONT></TD>
    <TD STYLE="width: 68%; font: 12pt Times New Roman, Times, Serif; text-align: justify; padding-left: 5.4pt; border-bottom: Black 1pt solid; border-right: Black 1pt solid; border-top: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">17
    April 2019</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify; border-bottom: Black 1pt solid; border-left: Black 1pt solid; border-right: Black 1pt solid; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Term</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 9.35pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unchanged</FONT></P>
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 9.35pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 9.35pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Appointment
on an on-going basis subject to customary probationary period and termination by either party.&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify; border-bottom: Black 1pt solid; border-left: Black 1pt solid; border-right: Black 1pt solid; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Fixed
    Remuneration</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-left: 5.4pt"><P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 9.35pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unchanged</FONT></P>
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 9.35pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 9.35pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remains
unchanged at $350,000 USD per annum comprising base salary and excluding statutory superannuation or equivalent.&nbsp;</FONT></P>
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 9.35pt 0pt 0; text-align: justify">&nbsp;</P>
        <P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 9.35pt 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Up
to $45,000 USD per annum for eligible health insurance and other employment related compensation.&nbsp;</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify; border-bottom: Black 1pt solid; border-left: Black 1pt solid; border-right: Black 1pt solid; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Short
    Term Incentives</B></FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify; padding-left: 5.4pt; border-bottom: Black 1pt solid; border-right: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Short
    Term Incentives of up to 50% of base salary to achieving key performance indicators to be defined by the Board</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify; border-bottom: Black 1pt solid; border-left: Black 1pt solid; border-right: Black 1pt solid; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Long
    Term Incentives</B></FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify; padding-left: 5.4pt; border-bottom: Black 1pt solid; border-right: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
    to shareholder approval - 5 million options exercisable at A$0.50 per option on or before 10 February 2024</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><P STYLE="margin-top: 0pt; text-align: right; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">Page 2 of&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</P></DIV>

    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img001_v1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img001_v1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 4@$4 P$1  (1 0,1 ?_$ .,   ,  P$! 0$!
M       )"@8'" L%! $# 0 " P$! 0$!            " 4&!PD$ P$"$
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MK#0<2S1*)A.X>.U"%,LJ(=*21.I9900(F4QQ !PVAH:RY52*&WM+>JW%22A
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MG&.+-&H>8J F60KUMKB@OJ[;:G.H+MV\DT2=IE1FZQ-(E4379.TQ\IPD8BA
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MW%0RW*/N^NTB1_-%?=$36=@0XDYV21  H@I@Z\%$1#<2[3%84W)_HB(AL/\
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M=0D*94P@'H 3#^/4[XLB?S[9T]0HWO6B(CPW) L]S5UFJ;]68<WSSP,]Y/\
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MNG9I.=ZVEIOZ.W[>E/X*7))^T!%IY.J'ZKA&VU55K4N,T*E_A*9!5]LQS?\
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M9'$2'-TG0,)=R*'*(&'G!DG'N88K<56V[T%0'03M4A"EMN"<@I"T@I4#]GM
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M6$<W<2#H2MV:*KE8H&4.(%( [CX:3/$[A2VG)[?<ZXE-'3UC3BR 20E"PI1
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(!!H@@T01_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img002_v1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img002_v1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ '0!> P$1  (1 0,1 ?_$ *0   $% 0$!
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M%VKHL<Q*Y8MQ:,G!6C<%V;42]@MFJP)@HW;B7P[""!>/AT<KI24%2I%&)$3
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8SNM-%W';SJDX@E7:RQY9YU<G6._%K__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
